Oculus Innovative Sciences Enters Into Agreement to Sell Ruthigen, Inc. Shares for $5.5 Million in Event of Ruthigen Merger Jan 12, 2015
Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015 Nov 13, 2014
Oculus Innovative Sciences Commercializes Microcyn(R)-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europe Nov 11, 2014
Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Scar Management Hydrogel Nov 4, 2014
Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Atopic Dermatitis Hydrogel Oct 30, 2014
Oculus Innovative Sciences Announces Fiscal Second Quarter 2015 Financial Results and Conference Call Oct 30, 2014
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of Four New Patents for Microcyn(R) Technology Sep 16, 2014
Oculus Innovative Sciences Introduces Microcyn(R)-Based Over-the-Counter Advanced Scar Management Hydrogel in United States Sep 10, 2014
Oculus Innovative Sciences Reports Revenues of $3.4 Million and Net Loss of $70,000 for First Quarter of Fiscal 2015 Aug 7, 2014
